US29089Q1058 - Common Stock
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with...
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA)...
Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning!
EBS earnings call for the period ending December 31, 2023.
EBS stock results show that Emergent BioSolutions missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Emergent BioSolutions (NYSE:EBS) just reported results for the fourth quarter o...
Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion,...
GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024,...
Investors in Emergent Biosolutions and EBS stock certainly have a big catalyst to cheer today, as the company announced a new CEO.
Joseph C. Papa has been appointed as the new president and CEO of Emergent BioSolutions, replacing Haywood Miller, effective February 21, 2024.
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md.,...
While it’s usually a good idea to trust Wall Street’s top experts, sometimes, it’s worthwhile to consider contrarian analyst picks.
GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health...
Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share.
EBS stock results show that Emergent BioSolutions missed analyst estimates for earnings per share but beat on revenue for the third quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Emergent BioSolutions (NYSE:EBS) just reported results for the third quarter of...